147 related articles for article (PubMed ID: 25131863)
1. [New era of the treatment of CRPC in Japan].
Akaza H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):804. PubMed ID: 25131863
[TBL] [Abstract][Full Text] [Related]
2. [Roles of medical oncologists in the new era of CRPC therapy in Japan].
Takahashi S
Gan To Kagaku Ryoho; 2014 Jul; 41(7):827-31. PubMed ID: 25131868
[TBL] [Abstract][Full Text] [Related]
3. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
4. [Current status and future direction of the treatment of CRPC (castration resistant prostate cancer)].
Akaza H
Nihon Rinsho; 2014 Dec; 72(12):2108-15. PubMed ID: 25518342
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy for CRPC].
Ozono S; Furuse H
Nihon Rinsho; 2014 Dec; 72(12):2170-3. PubMed ID: 25518353
[TBL] [Abstract][Full Text] [Related]
6. Current, new and novel therapy for castration-resistant prostate cancer.
Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
[TBL] [Abstract][Full Text] [Related]
7. [New therapies in metastatic castration resistant prostate cancer].
Thibault C; Massard C
Bull Cancer; 2015 Jun; 102(6):501-8. PubMed ID: 26022286
[TBL] [Abstract][Full Text] [Related]
8. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
9. [Role of urologists in the era of new treatment modalities for CRPC in Japan].
Ozono S
Gan To Kagaku Ryoho; 2014 Jul; 41(7):823-6. PubMed ID: 25131867
[TBL] [Abstract][Full Text] [Related]
10. New therapies for castration-resistant prostate cancer: efficacy and safety.
Beltran H; Beer TM; Carducci MA; de Bono J; Gleave M; Hussain M; Kelly WK; Saad F; Sternberg C; Tagawa ST; Tannock IF
Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
[TBL] [Abstract][Full Text] [Related]
11. Managed care implications in castration-resistant prostate cancer.
Lew I
Am J Manag Care; 2013 Dec; 19(18 Suppl):s376-81. PubMed ID: 24494692
[TBL] [Abstract][Full Text] [Related]
12. [Treatment sequence using newly developed agents for men with castration resistant prostate cancer].
Fujimoto N
Nihon Rinsho; 2014 Dec; 72(12):2193-7. PubMed ID: 25518357
[TBL] [Abstract][Full Text] [Related]
13. Current state of castration-resistant prostate cancer.
Petrylak DP
Am J Manag Care; 2013 Dec; 19(18 Suppl):s358-65. PubMed ID: 24494690
[TBL] [Abstract][Full Text] [Related]
14. Phytoestrogens selective for the estrogen receptor beta exert anti-androgenic effects in castration resistant prostate cancer.
Thelen P; Wuttke W; Seidlová-Wuttke D
J Steroid Biochem Mol Biol; 2014 Jan; 139():290-3. PubMed ID: 23872207
[TBL] [Abstract][Full Text] [Related]
15. The biology of castration-resistant prostate cancer.
Lian F; Sharma NV; Moran JD; Moreno CS
Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
[No Abstract] [Full Text] [Related]
16. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
Marech I; Vacca A; Ranieri G; Gnoni A; Dammacco F
Int J Oncol; 2012 May; 40(5):1313-20. PubMed ID: 22322981
[TBL] [Abstract][Full Text] [Related]
17. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in second-line treatment of castration-resistant prostate cancer.
Ong M; Winquist E
Curr Opin Support Palliat Care; 2011 Sep; 5(3):199-205. PubMed ID: 21734586
[TBL] [Abstract][Full Text] [Related]
19. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer.
Small EJ; Penson DF; Sartor O
Clin Adv Hematol Oncol; 2011 Jul; 9(7 Suppl 13):1-15. PubMed ID: 22361784
[TBL] [Abstract][Full Text] [Related]
20. [Qualitative and quantitative hormonal regulation in castration-resistant prostate cancer].
Murez T; Basset V; Audenet F; Lebret T; Branchereau J
Prog Urol; 2013 Oct; 23 Suppl 1():S1-8. PubMed ID: 24314734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]